Generic Name and Formulations:
Hepatitis A inactivated 720 ELISA Units (EL.U.), hepatitis B surface antigen (recombinant) 20mcg; per mL; susp for IM inj; aluminum adsorbed; contains trace amounts of thimerosal, formalin, neomycin, yeast protein.
Indications for TWINRIX:
Hepatitis A and hepatitis B immunization.
≥18yrs: 1 inj IM in deltoid area at 0-, 1-, and 6 months. Alternate 4-dose schedule: 1 inj IM in deltoid area at 0-, 7-, and 21 to 30-days followed by booster dose at month 12.
<18yrs: not recommended.
May defer in acute febrile illness or active infection. Bleeding disorders. Thrombocytopenia. Immunodeficiency: may get suboptimal response. Have epinephrine (1:1000) inj available. If given with immune globulin, use separate syringe and different site. Pregnancy (Cat.C). Nursing mothers.
Immunosuppressives may reduce efficacy.
Inj site reactions, headache, fatigue, GI upset, fever.
Register pregnant patients exposed to Twinrix by calling (888) 452-9622. Report adverse events to VAERS by calling (800) 822-7967.
Single-dose vials—1, 10; Single-dose prefilled syringes—5
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline